Cargando…
KAP1 silencing relieves OxLDL-induced vascular endothelial dysfunction by down-regulating LOX-1
KRAB domain-associated protein 1 (KAP1) is highly expressed in atherosclerotic plaques. Here, we studied the role of KAP1 in atherosclerosis development using a cell model of endothelial dysfunction induced by oxidative low-density lipoprotein (OxLDL). The phosphorylation and protein levels of KAP1...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7414520/ https://www.ncbi.nlm.nih.gov/pubmed/32725144 http://dx.doi.org/10.1042/BSR20200821 |
_version_ | 1783568983880892416 |
---|---|
author | Yan, Tianqing Liang, Chang Fan, Haidi Zhou, Wei Huang, Linyan Qi, Suhua Wang, Wan Ma, Ping |
author_facet | Yan, Tianqing Liang, Chang Fan, Haidi Zhou, Wei Huang, Linyan Qi, Suhua Wang, Wan Ma, Ping |
author_sort | Yan, Tianqing |
collection | PubMed |
description | KRAB domain-associated protein 1 (KAP1) is highly expressed in atherosclerotic plaques. Here, we studied the role of KAP1 in atherosclerosis development using a cell model of endothelial dysfunction induced by oxidative low-density lipoprotein (OxLDL). The phosphorylation and protein levels of KAP1 were similar between OxLDL-treated and non-treated endothelial cells (ECs). KAP1 depletion significantly inhibited the production of OxLDL-enhanced reactive oxygen species and the expression of adhesion molecules in ECs. Treatment with OxLDL promoted the proliferation and migration of ECs, which was also confirmed by the elevated levels of the proliferative markers c-Myc and PCNA, as well as the migratory marker MMP-9. However, these effects were also abrogated by KAP1 depletion. Moreover, the depletion of KAP1 in OxLDL-treated ECs resulted in decreases in the LOX-1 level and increases in eNOS expression. Generally, the data suggest that strategies targeting KAP1 depletion might be particularly useful for the prevention or treatment of atherosclerosis. |
format | Online Article Text |
id | pubmed-7414520 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Portland Press Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74145202020-08-13 KAP1 silencing relieves OxLDL-induced vascular endothelial dysfunction by down-regulating LOX-1 Yan, Tianqing Liang, Chang Fan, Haidi Zhou, Wei Huang, Linyan Qi, Suhua Wang, Wan Ma, Ping Biosci Rep Cardiovascular System & Vascular Biology KRAB domain-associated protein 1 (KAP1) is highly expressed in atherosclerotic plaques. Here, we studied the role of KAP1 in atherosclerosis development using a cell model of endothelial dysfunction induced by oxidative low-density lipoprotein (OxLDL). The phosphorylation and protein levels of KAP1 were similar between OxLDL-treated and non-treated endothelial cells (ECs). KAP1 depletion significantly inhibited the production of OxLDL-enhanced reactive oxygen species and the expression of adhesion molecules in ECs. Treatment with OxLDL promoted the proliferation and migration of ECs, which was also confirmed by the elevated levels of the proliferative markers c-Myc and PCNA, as well as the migratory marker MMP-9. However, these effects were also abrogated by KAP1 depletion. Moreover, the depletion of KAP1 in OxLDL-treated ECs resulted in decreases in the LOX-1 level and increases in eNOS expression. Generally, the data suggest that strategies targeting KAP1 depletion might be particularly useful for the prevention or treatment of atherosclerosis. Portland Press Ltd. 2020-08-07 /pmc/articles/PMC7414520/ /pubmed/32725144 http://dx.doi.org/10.1042/BSR20200821 Text en © 2020 The Author(s). https://creativecommons.org/licenses/by/4.0/ This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). |
spellingShingle | Cardiovascular System & Vascular Biology Yan, Tianqing Liang, Chang Fan, Haidi Zhou, Wei Huang, Linyan Qi, Suhua Wang, Wan Ma, Ping KAP1 silencing relieves OxLDL-induced vascular endothelial dysfunction by down-regulating LOX-1 |
title | KAP1 silencing relieves OxLDL-induced vascular endothelial dysfunction by down-regulating LOX-1 |
title_full | KAP1 silencing relieves OxLDL-induced vascular endothelial dysfunction by down-regulating LOX-1 |
title_fullStr | KAP1 silencing relieves OxLDL-induced vascular endothelial dysfunction by down-regulating LOX-1 |
title_full_unstemmed | KAP1 silencing relieves OxLDL-induced vascular endothelial dysfunction by down-regulating LOX-1 |
title_short | KAP1 silencing relieves OxLDL-induced vascular endothelial dysfunction by down-regulating LOX-1 |
title_sort | kap1 silencing relieves oxldl-induced vascular endothelial dysfunction by down-regulating lox-1 |
topic | Cardiovascular System & Vascular Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7414520/ https://www.ncbi.nlm.nih.gov/pubmed/32725144 http://dx.doi.org/10.1042/BSR20200821 |
work_keys_str_mv | AT yantianqing kap1silencingrelievesoxldlinducedvascularendothelialdysfunctionbydownregulatinglox1 AT liangchang kap1silencingrelievesoxldlinducedvascularendothelialdysfunctionbydownregulatinglox1 AT fanhaidi kap1silencingrelievesoxldlinducedvascularendothelialdysfunctionbydownregulatinglox1 AT zhouwei kap1silencingrelievesoxldlinducedvascularendothelialdysfunctionbydownregulatinglox1 AT huanglinyan kap1silencingrelievesoxldlinducedvascularendothelialdysfunctionbydownregulatinglox1 AT qisuhua kap1silencingrelievesoxldlinducedvascularendothelialdysfunctionbydownregulatinglox1 AT wangwan kap1silencingrelievesoxldlinducedvascularendothelialdysfunctionbydownregulatinglox1 AT maping kap1silencingrelievesoxldlinducedvascularendothelialdysfunctionbydownregulatinglox1 |